CPT code 0568U designates a Proprietary Laboratory Analyses (PLA) test — LucentAD™ Complete from Quanterix Corporation — that measures a panel of plasma protein biomarkers linked to Alzheimer’s disease and reports results as positive, intermediate, or negative for Alzheimer’s pathology. This molecular array assay quantifies beta amyloid (Aβ40 and Aβ42) and their ratio, phosphorylated tau (e.g., pTau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). The code matters nationally as blood-based biomarker testing for Alzheimer’s advances diagnostic pathways, influences care planning, and raises coverage and access considerations across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the test’s clinical purpose and service setting, an explanation of payer coverage landscapes and common billing modifiers, and context on how this PLA code fits into evolving Alzheimer’s diagnostics. The publication summarizes benchmarks and policy developments relevant to payer coverage decisions and provides clinical context for laboratory and outpatient settings. Data not available in the input is noted where applicable.